Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Johnson & Johnson
(NY:
JNJ
)
164.13
+1.78 (+1.10%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Johnson & Johnson
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END
Via
FinancialNewsMedia
3 Dividend Growth Stocks to Accumulate on Dips: August Edition
August 06, 2024
These three dividend growth stocks are among the best options for long-term investors seeking reliable total returns in this current market.
Via
InvestorPlace
The Market's Excessive Recession Fears
August 06, 2024
Today's Research Daily features a comment on updated research reports on 16 major stocks, including Johnson & Johnson, T-Mobile US, Inc., and Marsh & McLennan Companies, Inc., as well as a micro-cap...
Via
Talk Markets
Topics
Economy
Exposures
Economy
Large Cap Biopharma And Healthcare, A Port In A Storm
August 05, 2024
Healthcare and biopharma show nice gains in a volatile week.
Via
Talk Markets
Looking At Johnson & Johnson's Recent Unusual Options Activity
August 02, 2024
Via
Benzinga
Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry
August 01, 2024
Via
Benzinga
A Closer Look at 14 Analyst Recommendations For Johnson & Johnson
July 30, 2024
Via
Benzinga
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
3 Defensive Stocks Weathering the Market Storm
August 05, 2024
Despite last week's market downturn, JNJ, KO, and PG posted gains, demonstrating resilience and potentially serving as defensive safe-haven investments.
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Economy
US Equities
Johnson & Johnson Unusual Options Activity For July 29
July 29, 2024
Via
Benzinga
Looking Into Johnson & Johnson's Recent Short Interest
July 25, 2024
Via
Benzinga
The S&P 500 Had Its Worst July in a Decade. Should You Really Buy Stocks Now?
August 05, 2024
It's key to take a long-term view.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
August 03, 2024
These two healthcare companies have far more upside potential than Johnson & Johnson.
Via
The Motley Fool
Forget Johnson & Johnson: Another Healthcare Giant Is a Much Better Bet for Growth
August 02, 2024
Abbott Laboratories' growth rate may look comparable to Johnson & Johnson's, but in the long run it could become much higher.
Via
The Motley Fool
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
August 01, 2024
These cheap value stocks are priced right for any bargain hunters seeking deals in the market at the moment.
Via
InvestorPlace
7 Leading MedTech Stocks for Next-Gen Health Solutions
July 31, 2024
With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar.
Via
InvestorPlace
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
July 31, 2024
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates.
Via
InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
July 30, 2024
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns.
Via
Benzinga
Q3’s Rising Stars: 3 Dow Stocks for Your Must-Watch List
July 30, 2024
These Dow stocks to watch have all been beaten down over the past year or more but are now poised for a rebound.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
July 30, 2024
The healthcare sector, represented by the XLV ETF, has seen a resurgence, breaking out of a multi-year consolidation phase and surging almost 3% in July.
Via
MarketBeat
Topics
ETFs
Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
July 29, 2024
From
Johnson & Johnson
Via
Business Wire
Stocks Going Ex Dividend In August 2024
July 29, 2024
A short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors.
Via
Talk Markets
7 Long-Term Stocks to Buy on the Dip: July 2024
July 27, 2024
As investors begin to rotate out of tech stocks, it's time to look at these long-term stocks that are trading at an inviting discount.
Via
InvestorPlace
Could Johnson & Johnson's Troubles With Talc Lawsuits Finally Be Coming to an End?
July 27, 2024
Is it safe to buy Johnson & Johnson stock now?
Via
The Motley Fool
Topics
Lawsuit
Exposures
Financial
Legal
10 Health Care Stocks Whale Activity In Today's Session
July 26, 2024
Via
Benzinga
Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan
July 26, 2024
From
Beasley Allen Law Firm
Via
Business Wire
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
July 26, 2024
From
Ad Hoc Group of Counsel
Via
Business Wire
3 Stocks Reeling From Ruined Reputations: Can They Recover?
July 25, 2024
Unforced errors by each of these controversial stocks has sullied their reputations and recovering them will not be easy or cheap.
Via
InvestorPlace
3 Beaten-Down Value Stocks Poised for a Massive Comeback: July 2024
July 25, 2024
Investors might want to consider these beaten-down value stocks, each of which looks poised for a turnaround in the year's second half.
Via
InvestorPlace
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
July 24, 2024
Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.